Is evantumumab a targeted drug or an immune drug? What is its mechanism of action and treatment principle?

Amivantamab is a targeted drug that works by targeting specific receptors on tumor cells. Specifically, evantumumab is a bispecific antibody that targets both EGFR (epidermal growth factor receptor) and MET receptors. EGFR and MET are two common receptors associated with cancer progression and tumor growth, and they exhibit abnormally active signaling in a variety of cancers. By targeting these two receptors, evantumumab can effectively block the growth signals of tumor cells, thereby inhibiting tumor growth and metastasis.

The mechanism of action of evantumumab is not limited to targeted inhibition of receptor activity, but also has immunomodulatory functions. Through its dual targeting effect, evantumumab can trigger the immune system's response and enhance the recognition and attack of tumor cells by immune cells (such as T cells). This mechanism makes evantumumab not only a targeted drug, but also plays an immunotherapy role to a certain extent, enhancing the anti-tumor effect of the drug.

In terms of treatment principle, evantumumab is mainly used to treat non-small cell lung cancer (NSCLC) with EGFR and MET gene mutations. This type of cancer often has overexpression or mutations in these receptors, and these mutations cause the cancer cells to continue to grow and become resistant to conventional treatments. By targeting EGFR and MET, evantumumab can effectively block these signaling pathways, reduce the proliferation of tumor cells, and overcome drug resistance in some patients, thereby achieving anti-tumor effects.

In addition to non-small cell lung cancer, evantumumab is also being explored in studies to treat other types of cancer, such as head and neck cancer and other epidermal growth factor receptor (EGFR)-related malignancies. Studies have shown that evantumumab exhibits good efficacy in some tumor types, especially those with specific mutations or abnormalities in tumor cells. Therefore, evantumumab, as a targeted immunotherapy drug, provides a new treatment option for cancer patients, especially in some tumor types with poor response or resistance to treatment.

Reference materials:https://www.rybrevant.com/